Skip to main content
. 2012 Aug;28(8):844–851. doi: 10.1089/aid.2011.0253

Table 3.

Genotype Distributions and Statistical Comparisons of NKG2C Genotypes in Control and HIV Patients

Genotype distributions
 
 
 
HIV-infected patient
 
 
 
 
 
Risk category
Pretreatment virus load (copies/ml)
  Control All IVDA MSM <30,000 >30,000
−/− 13 5% 33 8% 6 7% 10 6% 5 11% 8 13%
+/− 71 25% 130 30% 19 20% 60 34% 8 17% 25 39%
+/+ 196 70% 270 62% 68 73% 105 60% 34 72% 31 48%
 
 
 
 
Progression category
          LTNP NP STP Other
        −/− 5 9% 9 7% 7 6% 11 9%
        +/− 11 19% 44 36% 33 29% 37 30%
        +/+ 42 72% 68 56% 74 65% 75 81%
Statistical comparisons
Comparison Genotype Significance Odds ratio 95% CI
Control vs. HIV −/− vs. −/+ and +/+   NS 0.59 0.31 to 1.14
  −/− and −/+ vs. +/+ * p=0.037 0.71 0.52 to 0.98
IVDA vs. MSM −/− vs. −/+ and +/+   NS 1.34 0.40 to 3.24
  −/− and −/+ vs. +/+ * p=0.044 0.55 0.32 to 0.96
LTNP vs. NP −/− vs. −/+ and +/+   NS 1.17 0.38 to 3.68
  −/− and −/+ vs. +/+ * p=0.049 0.49 0.25 to 0.96
LTNP vs. STP+NP −/− vs. −/+ and +/+   NS 1.29 0.45 to 3.68
  −/− and −/+ vs. +/+ - p=0.097 0.58 0.31 to 1.10
LTNP vs. rest −/− vs. −/+ and +/+   NS 1.16 0.43 to 3.14
  −/− and −/+ vs. +/+ - p=0.108 0.59 0.32 to 1.08
<30,000 vs. >30,000 (copies/ml) −/− vs. −/+ and +/+   NS 0.83 0.25 to 2.73
  −/− and −/+ vs. +/+ * p=0.019 2.78 1.24 to 6.23

IVDA, intravenous drug abuse; MSM, men who have sex with men; LTNP, long-term nonprogressor; NP, normal progressor; STP, short-term progressor; OR, odds ratio; CI, confidence interval.